STRICTLY EMBARGOED UNTIL Tuesday 6 September 2022 00:01 BST LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER First and only approved medicine in Great Britain which targets germline BRCA mutations in pati...